InMode Ltd.

Good day and welcome to InMode's second quarter 2024 earnings results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the conference over to Miri Sagal, CEO of MSIR. Please go ahead.

Thank you operator and everyone for joining us today. Welcome to InMode's conference call. Before we begin, I would like to remind our listeners that certain information provided on this call may contain forward-looking statements, and the safe harbor statement outlined in today's earnings release also pertains to this call. If you have not received a copy of the release, please visit the investor relations section of the company's IR website. Changes in business, competitive, technological, regulatory, and other factors could cause actual results differ materially from those expressed by the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them, except as required by law. With that, I'd like to pass the call over to Moshe Mizrachi, InMode's CEO. Moshe, please go ahead.

Thank you, Miri, and to everyone for joining us. With me today are Dr. Michael Kreindel, our Co-Founder and Chief Technology Officer, Yair Malka, our CFO, Shaquille Akani, our President in North America, our Medical Director and VP of Medical Affairs, Dr. Eran Krieger, and Raphael Liekeman, our VP of Finance. Following our prepared remarks, We will all be available for question and answer. I would like to highlight the development of the second quarter. As we previously mentioned in Q1, we launched our two new advanced platforms, IgniteRF and Optimus Max. We are happy to report that we have began deliveries of both platforms. and we believe we are on track to complete deliveries of pre-orders before the end of the year. We're happy to see strong demand, and we believe that these innovative platforms that offer several technologies and handpieces will be solid contributors in the coming year. Once again, IgniteRF is the next generation of our legacy RFAL technology. a minimally invasive platform with a new Morpheus 8 burst handpiece and the all-new Quantum RF, a new version minimally invasive static surgical procedure in a box. The Quantum RF handpiece has been recently cleared by the FDA. With the Ignite, physicians may adjust the depth of the power, allowing for more effective treatment in less time. These features are highly valued by physicians that aspire to shorten treatment time while achieving good results. The Optimus Max is a multi-application platform with Morpheus 8, non-invasive RF handpieces, IPL, and laser-based treatment. It is the most complicated device we have ever manufactured. and it has many features that doctors and patients desire, such as ability to deliver different energy levels at various depths, allowing for stronger results in less time and with less discomfort. The macroeconomic trend that we discussed on our last call impacted market demand as well as our financial results. The second quarter was a challenging one for us and for the aesthetic doctors. We have seen a major decrease in demand for treatment, mainly in the U.S. Our Israeli team is working longer shifts to ensure we maintain our commitment to timely deliveries. Their dedication and hard work are crucial to our success while maintaining our leadership position in the market. Earlier this month, we were happy to update that the FDA cleared Morpheus 8 for contraction soft tissue, the first and only of its kind. Our Morpheus 8 treatment has become the gold standard in aesthetic treatment and our most popular technology. Additionally, the new indication enable petitioner to expand their patient base. We continue to invest in R&D to provide medical professional with the advancement they need to deliver the highest quality of care to achieve best results. On the corporate level, I am pleased to introduce Dr. Ron Krieger as our Medical Director and VP of Medical Affairs. Dr. Krieger joined the company, joined InMod four years ago. He has 30 years of experience in medical aesthetics and has worked for several Italian and Israeli companies in the field. I would like to thank Dr. Spiro Tardous for his time with InMod and wish him best of luck in his future. Now, I would like to turn the call over to Michael, to Yair Malka, our CFO.